Updates on molecular targeted therapies for intraparenchymal cns metastases

Akanksha Sharma*, Lauren Singer, Priya Kumthekar

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Central nervous system (CNS) metastases can occur in a high percentage of systemic cancer patients and is a major cause of morbidity and mortality in these patients. Almost any histology can find its way to the brain, but lung, breast, and melanoma are the most common pathologies seen in the CNS from metastatic disease. Identification of many key targets in the tumorigenesis pathway has been crucial to the development of a number of drugs that have demonstrated successful penetration of the blood–brain, blood–cerebrospinal fluid, and blood–tumor barriers. Targeted therapy and immunotherapy have dramatically revolutionized the field with treatment options that can provide successful and durable control of even CNS disease. In this review, we discuss major targets with successful treatment options as demonstrated in clinical trials. These include tyrosine kinase inhibitors, monoclonal antibodies, and antibody–drug conjugates. We also provide an update on the state of the field and highlight key upcoming trials. Patient-specific molecular information combined with novel therapeutic approaches and new agents has demonstrated and continues to promise significant progress in the management of patients with CNS metastases.

Original languageEnglish (US)
Article number17
Issue number1
StatePublished - Jan 1 2022


  • CNS disease
  • Immunotherapy
  • Intraparenchymal metastases
  • Metastatic disease
  • Monoclonal antibodies
  • Targeted therapy
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Updates on molecular targeted therapies for intraparenchymal cns metastases'. Together they form a unique fingerprint.

Cite this